Tuesday, 20 September 2022

COMPANY UPDATE

Syarikat Takaful Malaysia Keluarga (STMB MK)

Growth Momentum Intact

After yesterday's meeting with STMB, we are now fairly optimistic of the group's recovery prospects in 2022. More importantly, management has reaffirmed that the risk of a cash call remains low while current dividend can be maintained even under the MFRS17 regime, which has been one of the lingering concerns of the investment community. Maintain BUY and target price of RM4.80 (12.0x 2022F PE), in line with its 10-year historical mean.

WHAT'S NEW

- Premium growth remains robust. Management alluded that overall group premium growth momentum remains promising with 2H22 premium yoy growth likely to mirror 1H22's 13% growth rate. This is above our current 9% yoy full-year assumption and is hovering at the upper end of the group's 11-13% premium growth target. For 2023, management remains confident in sustaining a similar growth rate with a slight slowdown in Mortgage Reducing Term Takaful (MRTT) growth to be offset by stronger personal financing premium growth, while general takaful growth is likely to remain robust, underpinned by fire premium growth.
- General insurance an outperformer. Syarikat Takaful Malaysia Keluarga (STMB) reported a 19% yoy growth in general takaful premium in 1H22. The strong growth was sustained by the non-motor segment (51% of general takaful premium base), and in particular fire, which is on track to record a 25% yoy growth in 2022. In comparison, conventional fire premium growth for the overall industry expanded at a much softer 4.6% yoy growth in 1H22. STMB's strategy to cross-sell its fire insurance products to its MRTT customers is bearing fruit. More importantly, this is an example of potential low-hanging cross-selling and upselling opportunities that STMB can tap on to sustain strong premium growth in the medium term.
- Family Takaful humming along. Despite STMB's market leading position within the Family Takaful segment (bancatakaful and Lembaga Pembiayaan Perumahan Sektor Awam scheme (LPPSA)), management remains confident in sustaining a 10-13% premium growth, underpinned by its bancatakaful business (77% of Family Takaful premium). Within its bancatakaful business, personal financing takaful remains the main engine of growth, expanding 22% yoy in 1H22 while MRTT came in at 8% yoy. Defending its market-leading bancatakaful position will include retaining its key partners (Bank Rakyat, RHB, and Bank Islam) while increasing the wallet share of takaful products from its key Bancatakaful partners. As for LPPSA (50% share), STMB will continue to leverage on its strong distribution network.
- Diversifying out of single contribution business as an additional engine of long-term growth. The group has a leading market share in the takaful single premium category (bancassurance and LPPSA), resulting in single premium products currently contributing 80-85% of the group's Family Takaful gross premium base. As such, management has set its sights on raising the contribution from regular premium products such as investment-linked products by enhancing its digital offerings of such products.

KEY FINANCIALS

| Year to 31 Dec (RMm) | 2020 | 2021 | 2022F | 2023F | 2024F |
|----------------------------|---------|---------|---------|---------|---------|
| Gross written premiums | 2,514.1 | 2,766.4 | 3,070.3 | 3,346.6 | 3,647.8 |
| Net earned premiums | 2,073.0 | 2,243.1 | 2,486.9 | 2,710.7 | 2,954.7 |
| Underwriting profit/(loss) | 533.9 | 580.4 | 540.1 | 600.5 | 726.2 |
| Net profit (rep./act.) | 362.4 | 411.4 | 323.1 | 389.4 | 438.0 |
| Net profit (adj.) | 362.4 | 411.4 | 323.1 | 389.4 | 438.0 |
| EPS (sen) | 44.4 | 50.3 | 39.5 | 47.5 | 53.3 |
| PE (x) | 7.5 | 6.6 | 8.4 | 7.0 | 6.2 |
| Dividend yield (%) | 3.6 | 3.6 | 4.7 | 5.7 | 6.0 |
| Total investment yield (%) | 6.5 | 7.5 | 6.6 | 6.4 | 6.1 |
| Combined ratio (%) | 70.9 | 73.0 | 77.1 | 76.7 | 75.4 |
| ROE (%) | 26.5 | 25.5 | 17.8 | 19.2 | 19.3 |
| Consensus net profit | - | - | 327.0 | 369.0 | 394.0 |
| UOBKH/Consensus (x) | - | - | 1.0 | 1.1 | 1.1 |

Source: STMK, Bloomberg, UOB Kay Hian

BUY

(Maintained)

| Share Price | RM3.31 |
|--------------|--------|
| Target Price | RM4.80 |
| Upside | +45.0% |

COMPANY DESCRIPTION

Insurance service provider that offers life and property insurance products through its subsidiaries.

STOCK DATA


| GICS sector | Financials |
|---------------------------------|------------|
| Bloomberg ticker: | STMB MK |
| Shares issued (m): | 837.3 |
| Market cap (Rmm): | 2,771.5 |
| Market cap (US\$m): | 609.2 |
| 3-mth avg daily t'over (US\$m): | 0.3 |

Price Performance (%)

| 52-week high/low | | | Rm4.33/Rm3.15 | | |
|------------------|------------|-------|---------------|--------|--|
| 1mth | 3mth | 6mth | 1yr | YTD | |
| (0.6) | (1.8) | (2.6) | (23.0) | (10.5) | |
| Major S | hareholder | s | | % | |
| LTH | | | | 28.2 | |
| EPF | | | | 11.8 | |
| | | | | | |

FY21 NAV/Share (Rm) 2.33

PRICE CHART



Source: Bloomberg

ANALYST(S)

Keith Wee Teck Keong

+603 2147 1981

keithwee@uobkayhian.com



Tuesday, 20 September 2022

- Expansion strategy. The three areas STMB wants to expand further are: a) general takaful segment, b) retail business, along with c) digitalisation. For general takaful, management will employ a two-pronged strategy to grow gross earned contribution by embarking on product innovation and pushing for more online distribution. As for its retail business, the focus is on recurring gross earned premiums, where STMB sees low-hanging opportunities in this space and looks to capitalise via cross- and upselling; channel priorities are direct and digital, followed by Bancatakaful, given less intense investment outlay vs the agency model.
- MFRS17 impact: Lower net profit offset by higher ROE. Management alluded that the
 transition to MFRS17 from MFRS4 may see profit falling by 15-20% but ROE possibly
 jumping 6ppt due to retained profit reclassification to contractual service margin (CSM)
 liability, resulting in a 30-45% decline in book value. Also, MFRS17 profit is expected to
 normalise back to MFRS4 level within six years with only the booking of earned CSM profit,
 not including new business growth.
- No changes to capital adequacy framework until 2025. More importantly, despite the implementation of MFRS17 in 2023, Bank Negara Malaysia (BNM) has allowed insurers to continue applying the current Risk Based Capital Framework until 2025. This essentially allows the group to recognise its CSM liability as retained earnings and consequently, capital, which removes any risk of an equity cash call. We believe that BNM's intention is to allow insurance companies sufficient gestation period to build up their retained earnings post MFRS17 adoption, thereby reducing the risk of a cash call even when BNM eventually changes the capital adequacy framework on risk charge in 2025.
- Maintaining dividend payouts even under MFRS17. Management alluded that under the MFRS17 regime, they will still be able to sustain the 12 sen DPS that was paid out in 2020 and 2021. Overall, we continue to be nonchalant with the adoption of MFRS17, as the new accounting standard does not alter the business nature and cash flow of single contribution products, and does not require capital injection.

EARNINGS REVISION/RISK

No change.

VALUATION/RECOMMENDATION

• Maintain BUY and target price of RM4.80. In an attempt to smoothen out the one-off impact of Cukai Makmur to our target price, we peg our valuations to an average of 2022 and 2023 earnings. Our target price is also based on a blended SOTP of P/B and PE, and implies a 12.0x 2022/23F EPS which is largely in line with its 10-year historical mean PE. The stock is trading at an undemanding –2.0SD to its historical 10-year mean PE, coupled with expectations of a recovery in premium trends in tandem with the economic reopening.

ENVIRONMENTAL, SOCIAL, GOVERNANCE (ESG) UPDATES

Environmental

Reduce usage of water, electricity. Management is committed to taking proactive
measures to preserve the environment by setting targets to reduce the use of water,
electricity and paper across the group.


Social

Enhancing financial assistance to the needy. The group has launched two
programmes namely Takaful myJalinan Kasih and Takaful myJalinan limu. The former
programme aims to provide monetary assistance to the needy (eg orphans and single
mothers), while the latter programme complements the work of school teachers by
helping students to excel their studies.

Governance


- Non-independent board of directors composition. The board consists of four independent non-executive directors and two non-independent non-executive directors.
- **Tenure cap on directors.** The group has also adopted a nine-year policy cap for its independent non-executive directors.

TRADING BELOW -2SD TO MEAN PBV



Source: STMK, UOB Kay Hian

TRADING AT -2SD TO MEAN PE



Source: STMK, UOB Kay Hian

VALUATION METRICS

| | 2022F | 2023F |
|--|---------|--------|
| EPS (sen) | 39.0 | 47.0 |
| Ascribed historical mean PER | 12.0x | 12.0x |
| Fair valuation based on PE methodology (RM) | RM 4.65 | RM5.60 |
| Book value/share | RM2.32 | RM2.60 |
| Ascribing P/B multiplier (Gordon growth derived, FY22: 19% ROE, FY23: 20.5% ROE) | 1.74x | 1.92x |
| Fair valuation based on P/B methodology | RM 4.05 | RM4.99 |
| Blended PE & P/B methodology | RM 4.34 | RM5.29 |
| TP: RM4.80 | | |

Source: UOB Kay Hian



Tuesday, 20 September 2022

| PROFIT & LOSS | | | | | BALANCE SHEET | | | | |
|----------------------------------|-------|---------|---------|---------|----------------------------------|--------|--------|--------|--------|
| Year to 31 Dec (RMm) | 2021 | 2022F | 2023F | 2024F | Year to 31 Dec (RMm) | 2021 | 2022F | 2023F | 2024F |
| Gross written premiums | 2,766 | 3,070 | 3,347 | 3,648 | Cash | 814 | 911 | 750 | 301 |
| Premium ceded to reinsurers | (523) | (583) | (636) | (693) | Loans and advances | 2,848 | 2,946 | 3,072 | 3,199 |
| Net earned premiums | 2,243 | 2,487 | 2,711 | 2,955 | Investments (equity & fixed inc) | 6,932 | 7,317 | 7,732 | 8,434 |
| Reinsurance commission income | 0 | 0 | 0 | 0 | Premiums receivables | 444 | 449 | 454 | 460 |
| Claims and insurance benefits | (949) | (1,169) | (1,274) | (1,359) | Fixed assets (incl prop) | 25 | 26 | 27 | 28 |
| G&A exp of insurance ops | (239) | (256) | (267) | (249) | Other assets | 1,547 | 1,807 | 2,345 | 2,936 |
| Other exp of insurance opss | (475) | (522) | (569) | (620) | Total assets | 12,611 | 13,456 | 14,380 | 15,357 |
| Underwriting profit/(loss) | 580 | 540 | 600 | 726 | Insurance payables | 1,087 | 1,152 | 1,220 | 1,292 |
| Investment income | 429 | 495 | 505 | 515 | Insurance contract liabilties | 9,778 | 10,365 | 10,987 | 11,646 |
| Interest inc. (Banking ops) | 0 | 0 | 0 | 0 | Total liabilities | 10,865 | 11,517 | 12,207 | 12,938 |
| Other income | 95 | 3 | 3 | 3 | Shareholders' funds | 1,713 | 1,907 | 2,141 | 2,386 |
| G&A exp of non-insurance ops | 0 | 0 | 0 | 0 | Minority interest - accumulated | 33 | 33 | 33 | 33 |
| Pre-tax profit | 439 | 477 | 510 | 564 | Total equity & liabilities | 12,611 | 13,456 | 14,380 | 15,357 |
| Tax | (27) | (155) | (122) | (128) | | | | | |
| Minorities | (1) | 1 | 2 | 2 | | | | | |
| Net profit | 411 | 323 | 389 | 438 | | | | | |
| Net profit (adj.) | 411 | 323 | 389 | 438 | | | | | |
| OPERATING RATIOS | | | | | KEY METRICS | | | | |
| Year to 31 Dec (%) | 2021 | 2022F | 2023F | 2024F | Year to 31 Dec (%) | 2021 | 2022F | 2023F | 2024F |
| Capital-related | | | | | Growth | | | | |
| Shareholders' funds/total assets | 13.6 | 14.2 | 14.9 | 15.5 | Gross premiums, yoy chg | 10.0 | 11.0 | 9.0 | 9.0 |
| Total Assets/equity (x) | 7.4 | 7.1 | 6.7 | 6.4 | Investment income, yoy chg | (0.2) | 15.3 | 2.0 | 2.0 |
| | | | | | Net profit, yoy chg | 13.5 | (21.5) | 20.5 | 12.5 |
| Liquidity | | | | | Profitability | | | | |
| Liquid assets/total assets | 32.5 | 32.6 | 31.3 | 27.8 | Loss ratio | 42.3 | 47.0 | 47.0 | 46.0 |
| • | | | | | Expense ratio | 30.7 | 30.1 | 29.7 | 29.4 |
| Valuation (%) | | | | | Combined ratio | 73.0 | 77.1 | 76.7 | 75.4 |
| Adjusted P/E (x) | 6.8 | 8.7 | 7.2 | 6.4 | Net investment yield | 7.5 | 6.6 | 6.4 | 6.1 |
| Dividend Yield | 3.5 | 4.6 | 5.5 | 5.8 | Total investment yield | 7.5 | 6.6 | 6.4 | 6.1 |
| Payout ratio | 23.9 | 39.5 | 39.5 | 36.9 | Reported ROE | 25.5 | 17.8 | 19.2 | 19.3 |
| - | | | | | Adjusted ROE | 25.5 | 17.8 | 19.2 | 19.3 |



Tuesday, 20 September 2022

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Tuesday, 20 September 2022

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

| ollowing table. | |
|-----------------|--|
| General | This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or |
| | located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to |
| | applicable law or regulation. |
| Hong Kong | This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the |
| | Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has |
| | trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed |
| | corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under |
| | Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong |
| | Kong and contains research analyses or reports from a foreign research house, please note: |
| | (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong |
| | Kong in respect of any matters arising from, or in connection with, the analysis or report; and |
| | (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong |
| | who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the |
| | analyses or reports only to the extent required by law. |
| Indonesia | This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority |
| | of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a |
| | foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant |
| | foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report. |
| Malaysia | Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the |
| | recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, |
| | at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the |
| | registered person under CMSA to distribute any research analyses in Malaysia. |
| Singapore | This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital |
| | markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the |
| | report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: |
| | (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore |
| | in respect of any matters arising from, or in connection with, the analysis or report; and |
| | (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore |
| | who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the |
| | contents of the analyses or reports only to the extent required by law. |
| Thailand | This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated |
| | by the Securities and Exchange Commission of Thailand. |
| United | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning |
| Kingdom | of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in |
| | the UK is intended only for institutional clients. |
| United | This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. |
| States of | laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its |
| America | contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in |
| ('U.S.') | the report should contact UOB Kay Hian (US) Inc. directly. |

Copyright 2022, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W